
## ASO VISUAL ABSTRACT

## ASO Visual Abstract: Treatment of Peritoneal Metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy—Results from the Prospective PIPAC-OPC2 Study

M. Graversen, MD, PhD<sup>1,2,3,4,5</sup>, S. Detlefsen, MD, PhD<sup>1,4,5,6</sup>, A. P. Ainsworth, MD, PhD<sup>1,2,4</sup>, C. W. Fristrup, MD, PhD<sup>1,2,4</sup>, A. O. Knudsen, MD<sup>1,7</sup>, P. Pfeiffer, MD, PhD<sup>1,4,5,7</sup>, L. S. Tarpgaard, MD, PhD<sup>1,5,7</sup>, and M. B. Mortensen, MD, PhD, DMSci<sup>1,2,4,5</sup>

<sup>1</sup>Odense PIPAC Center, Odense University Hospital, Odense, Denmark; <sup>2</sup>Department of Surgery, Odense University Hospital, Odense, Denmark; <sup>3</sup>OPEN – Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark; <sup>4</sup>OPAC - Odense Pancreas Center, Odense University Hospital, Odense, Denmark; <sup>5</sup>Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; <sup>6</sup>Department of Pathology, Odense University Hospital, Odense, Denmark; <sup>7</sup>Department of Oncology, Odense University Hospital, Odense, Denmark

Pressurized IntraPeritoneal Aerosol Chemotherapy is a safe treatment in patients with peritoneal metastasis. In the largest prospective, controlled study to date, we show that the Peritoneal Regression Grading score holds significant prognostic information (https://doi.org/10.1245/s10434-02 2-13010-0).



© Society of Surgical Oncology 2023

Published Online: 24 January 2023

M. Graversen, MD, PhD

e-mail: martin.graversen@rsyd.dk

**DISCLOSURE** The authors have no commercial interests and received no financial or material support for this study.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.